BioAge Labs (BIOA) Insider: 22,000 Stock Options Granted to Director

Rhea-AI Filing Summary

BioAge Labs insider grant: Director Pande Vijay Satyanand was granted 22,000 stock options on 08/07/2025 allowing purchase of common stock at an exercise price of $4.32. The filing reports the award as a derivative security acquired and shows 22,000 derivative securities beneficially owned following the transaction, held in a direct form of ownership. The option award's vesting is explicit: it vests in full on the earlier of the next annual meeting or the one-year anniversary of the grant date, subject to continued service. The award appears to expire on 08/06/2035. The form is signed by an attorney-in-fact on 08/11/2025.

Positive

• 22,000 options granted to a director, aligning management incentives with shareholder value
• Vesting is clear: vests in full on earlier of next annual meeting or one-year anniversary, which ties incentives to near-term performance

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine director option grant of 22,000 shares at $4.32, structured with short-term vesting tied to continued service.

The grant delivers 22,000 stock options to a company director with an exercise price of $4.32. Vesting occurs in full on the earlier of the next annual meeting or one year from grant, which aligns near-term retention incentives with shareholder timelines. The options are reported as directly owned and the filing identifies an expiration date of 08/06/2035. For investors, this is a standard equity-compensation event documented on Form 4; the filing does not include market-price context or any additional cash payments or sales.

Corporate Governance Expert

TL;DR: Governance-wise this is a typical time-based option award with full vesting tied to service and the next shareholder meeting.

The disclosure specifies the full-vesting condition and direct ownership, which provides clarity on timing and control. The one-year or next-meeting vesting condition creates a near-term alignment between the director and shareholders. The Form 4 includes the required signatures and dates but contains no further details about board approvals or aggregate outstanding dilution. The information is material for tracking insider incentives but does not itself indicate unusual governance actions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pande Vijay Satyanand

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

1445A SOUTH 50TH STREET

(Street)

RICHMOND CA 94804

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.32	08/07/2025		A		22,000		(1)	08/06/2035	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did BIOA director Pande Vijay Satyanand report on Form 4?

The director reported acquisition of 22,000 stock options (derivative securities) on 08/07/2025.

What is the exercise price and number of options in the BIOA Form 4?

The options have an exercise (conversion) price of $4.32 and total 22,000 options were reported.

When do the BioAge options vest and when do they expire?

The award vests in full on the earlier of the next annual meeting or one-year anniversary of the grant date, and the filing lists an expiration date of 08/06/2035.

Is the ownership form direct or indirect for the reported BIOA options?

The Form 4 indicates the options are held in a Direct (D) form of beneficial ownership.

Who signed the Form 4 and when was it filed?

The form was signed by Dov A. Goldstein as attorney-in-fact on 08/11/2025, reporting the 08/07/2025 transaction.